aod9604 human trials Onset Half Life aod9604 human clinical trials results
Description
Ready to boost your wellness journey
Hepatic metabolic dysfunction contributes to fatty liver disease, cirrhosis, and other conditions
The first gap is species
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Taking a pill takes seconds, you can do it anywhere, and there are no needles, which matters for anyone with a needle phobia
